Search

Search Constraints

You searched for: Author/Creator Laing, Robert

Search Results

1. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Issue 7 (July 2017)

2. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Issue 10024 (19th March 2016)

3. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Issue 10274 (13th February 2021)

4. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Issue 10349 (30th July 2022)

5. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Issue 10325 (12th February 2022)

6. Does prostate HistoScanning™ play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies. (20th March 2014)

9. Hemi‐ablative low‐dose‐rate prostate brachytherapy for unilateral localised prostate cancer. (23rd December 2019)

10. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Issue 10387 (6th May 2023)